Selvita S.A. (SLV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Selvita S.A. (SLV) has a cash flow conversion efficiency ratio of 0.090x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł29.01 Million ≈ $7.98 Million USD) by net assets (zł321.73 Million ≈ $88.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Selvita S.A. defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Selvita S.A. - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Selvita S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Selvita S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Selvita S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kiler Gayrimenkul Yatirim Ortakligi AS
IS:KLGYO
|
0.001x |
|
DIRECTA SIM SPA
F:ZP7
|
N/A |
|
Harvard Ave Acquisition Corporation Class A Ordinary Share
NASDAQ:HAVA
|
-0.002x |
|
United Paper Public Company Limited
BK:UTP
|
0.036x |
|
Ilyang Pharmaceutical Co Ltd
KO:007575
|
0.009x |
|
UmweltBank AG
XETRA:UBK
|
-0.132x |
|
Aurum Resources Ltd
AU:AUE
|
-0.004x |
|
Pro-Dex Inc
NASDAQ:PDEX
|
0.086x |
Annual Cash Flow Conversion Efficiency for Selvita S.A. (2015–2025)
The table below shows the annual cash flow conversion efficiency of Selvita S.A. from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Selvita S.A. market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | zł321.73 Million ≈ $88.54 Million |
zł73.26 Million ≈ $20.16 Million |
0.228x | +14.39% |
| 2024-12-31 | zł321.88 Million ≈ $88.59 Million |
zł64.07 Million ≈ $17.63 Million |
0.199x | -17.57% |
| 2023-12-31 | zł327.07 Million ≈ $90.01 Million |
zł78.98 Million ≈ $21.74 Million |
0.241x | -12.55% |
| 2022-12-31 | zł273.16 Million ≈ $75.18 Million |
zł75.43 Million ≈ $20.76 Million |
0.276x | -35.11% |
| 2021-12-31 | zł205.55 Million ≈ $56.57 Million |
zł87.47 Million ≈ $24.07 Million |
0.426x | +121.29% |
| 2020-12-31 | zł152.66 Million ≈ $42.01 Million |
zł29.36 Million ≈ $8.08 Million |
0.192x | +113.17% |
| 2019-12-31 | zł47.66 Million ≈ $13.12 Million |
zł4.30 Million ≈ $1.18 Million |
0.090x | -61.73% |
| 2018-12-31 | zł49.19 Million ≈ $13.54 Million |
zł11.60 Million ≈ $3.19 Million |
0.236x | -16.47% |
| 2017-12-31 | zł37.34 Million ≈ $10.28 Million |
zł10.54 Million ≈ $2.90 Million |
0.282x | +350.36% |
| 2016-12-31 | zł55.71 Million ≈ $15.33 Million |
zł-6.28 Million ≈ $-1.73 Million |
-0.113x | +67.84% |
| 2015-12-31 | zł46.88 Million ≈ $12.90 Million |
zł-16.43 Million ≈ $-4.52 Million |
-0.350x | -- |
About Selvita S.A.
Selvita S.A. provides drug discovery, drug development, and contract testing services in Poland. The company offers computer-aided drug design and artificial intelligence solutions, including structure-based drug design, virtual screening, and bioinformatics; medicinal and synthetic, analytical, and solid state chemistry, as well as process chemistry and scale up, and compound management and libr… Read more